In Vitro Study of the Synergistic Effect of an Enzyme Cocktail and Antibiotics against Biofilms in a Prosthetic Joint Infection Model

Hervé Poilvache,[a,b,c] Albert Ruiz-Sorribas,[b] Olivier Cornu,[a,c] Françoise Van Bambeke[b]

[a]Université catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Neuromusculoskeletal Laboratory, Brussels, Belgium
[b]Université catholique de Louvain, Louvain Drug Research Institute, Pharmacologie cellulaire et moléculaire, Brussels, Belgium
[c]Cliniques Universitaires Saint-Luc, Orthopedic Surgery Department, Brussels, Belgium

ABSTRACT Prosthetic joint infections (PJI) are frequent complications of arthroplasties. Their treatment is made complex by the rapid formation of bacterial biofilms, limiting the effectiveness of antibiotic therapy. In this study, we explore the effect of a tri-enzymatic cocktail (TEC) consisting of an endo-1,4-β-D-glucanase, a β-1,6-hexosaminidase, and an RNA/DNA nonspecific endonuclease combined with antibiotics of different classes against biofilms of *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Escherichia coli* grown on Ti-6Al-4V substrates. Biofilms were grown in Trypticase soy broth (TSB) with 10 g/liter glucose and 20 g/liter NaCl (TGN). Mature biofilms were assigned to a control group or treated with the TEC for 30 min and then either analyzed or reincubated for 24 h in TGN or TGN with antibiotics. The cytotoxicity of the TEC was assayed against MG-63 osteoblasts, primary murine fibroblasts, and J-774 macrophages using the lactate dehydrogenase (LDH) release test. The TEC dispersed 80.3 to 95.2% of the biofilms' biomass after 30 min. The reincubation of the treated biofilms with antibiotics resulted in a synergistic reduction of the total culturable bacterial count (CFU) compared to that of biofilms treated with antibiotics alone in the three tested species (additional reduction from 2 to more than 3 $\log_{10}$ CFU). No toxicity of the TEC was observed against the tested cell lines after 24 h of incubation. The combination of pretreatment with TEC followed by 24 h of incubation with antibiotics had a synergistic effect against biofilms of *S. aureus*, *S. epidermidis*, and *E. coli*. Further studies should assess the potential of the TEC as an adjuvant therapy in *in vivo* models of PJI.

KEYWORDS *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Escherichia coli*, biofilms, dispersin B, endonuclease, cellulase, prosthetic joint infection, antibiotics, coagulase-negative staphylococci, enzymes, prosthesis infections

Prosthetic joint infections (PJI) are catastrophic complications of joint replacement surgeries. With a prevalence of 2.0% to 2.4% in patients following a total knee or total hip replacement (1), PJIs represent one of the leading causes of failure for arthroplasties (2).

The most prevalent species encountered in PJIs are *Staphylococcus aureus*, coagulase-negative staphylococci, streptococci, and Gram-negative bacilli (3). These species are known to adhere to the surfaces of implants and to form complex communities embedded in an extracellular matrix called biofilms. In these structures, bacteria become tolerant to antibiotics up to concentrations 1,000 times the MIC of planktonic cells (4–6).

Surgical debridement, implant retention, and antibiotic therapy (DAIR) is the preferred treatment strategy of acute (less than 3 weeks of symptoms) PJI (7), with better functional outcomes (8) and lower costs (9, 10) than alternative strategies. However,

TABLE 1 MICs and minimal biofilm eradication concentrations[a]

Antibiotic	Assay	MIC or MBEC value (mg/liter)					
		ATCC 33591		ATCC 35984		ATCC 47076[b]	
		MHB-ca	TGN	MHB-ca	TGN	MHB-ca	TGN
Daptomycin	MIC	1	1	1	1		
	MBEC	4	>1,024	>1,024	>1,024		
Doxycycline	MIC	**16**	**16**	0.25	0.25		
	MBEC			128	512		
Linezolid	MIC	2	1	2	1		
	MBEC	8	>1,024	>1,024	>1,024		
Moxifloxacin	MIC	0.125	0.125	0.06	0.125		
	MBEC	2	>1,024	>1,024	>1,024		
Rifampin	MIC	0.004	0.004	0.004	0.004		
	MBEC	8	2	128	4		
Vancomycin	MIC	1	8	2	8		
	MBEC	>1,024	>1,024	>1,024	>1,024		
Ceftazidime	MIC					0.25	0.125
	MBEC					>1,024	
Ciprofloxacin	MIC					0.016	0.03
	MBEC					128	
Colistin	MIC					0.5	0.25
	MBEC					>1,024	
Meropenem	MIC					0.03	0.06
	MBEC					>256	

[a]Values in bold indicate an MIC superior to the CLSI breakpoint values (50).
[b]The MBEC assay results for the ATCC 47076 strain were unreliable and were not included.

the observed failure rate is considerable (11, 12). These failures are partly explained by an insufficient biofilm removal during the debridement surgery, as was shown *in vitro* by Urish et al. (13) and Poilvache et al. (14).

As a consequence, the need for new adjuvant treatments to facilitate the dispersal of biofilms has been recognized in the literature (15–19). Among mechanical and pharmaceutical approaches, the use of hydrolytic enzymes targeting specific components of the biofilm matrix has been suggested (19). The dispersal potential of single enzymes targeting individual matrix components, such as extracellular DNA (eDNA), exopolysaccharides, or extracellular proteins, has been demonstrated by previous authors in *in vitro* models (20–23). Moreover, the synergy of the combination of these enzymes with antibiotics (24, 25) or antiseptics (26, 27) against biofilms has been reported in previous studies.

However, these previous studies did not address the variety in matrix composition among bacterial species, as they focused on the effect of single enzymes on selected species. For this reason, a broad-spectrum tri-enzymatic cocktail (hereafter referred to as TEC for tri-enzymatic cocktail), composed of an endo-1,4-β-D-glucanase, a β-1,6-hexosaminidase, and a recombinant RNA/DNA nonspecific endonuclease (see Materials and Methods), was tested, targeting the matrix of *Escherichia coli*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Staphylococcus epidermidis* biofilms (patent numbers WO2017/211737 A1 [28] and BE2020/5726 [29]).

In this study, we investigated the dispersal effect of this tri-enzyme cocktail against *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Escherichia coli* monomicrobial biofilms grown *in vitro* on titanium alloy surfaces similar to prosthetic implants and examined its synergy in combination with a broad selection of antibiotics belonging to different classes recommended for PJI treatment (7) at concentrations relevant to human use.

RESULTS

Antibiotic susceptibility of planktonic bacteria and of biofilms. The MICs and minimal biofilm eradication concentrations (MBECs) are shown in Table 1. The strains

TABLE 2 Antibiotics experimental concentrations and rationales

Antibiotic	Concn (mg/liter)	Rationale[a]
Daptomycin	30	$\dfrac{AUC_{0-24\,h}}{24\,h}$
Doxycycline	1.5	$\dfrac{AUC_{0-24\,h}}{24\,h}$
Linezolid	5	C_{min}[b]
Moxifloxacin	1.5	$\dfrac{AUC_{0-24\,h}}{24\,h}$
Rifampin	2.5	$\dfrac{AUC_{0-24\,h}}{24\,h}$
Vancomycin	2	Target trough concn (20 mg/liter)
Ceftazidime	3.8	C_{min}
Ciprofloxacin	1.625	$\dfrac{AUC_{0-24\,h}}{24\,h}$
Colistin	2.5	$\dfrac{AUC_{0-24\,h}}{24\,h}$
Meropenem	0.25	C_{min}

[a]Pharmacokinetic and PK/PD information obtained from the EUCAST rationales for clinical breakpoint documents or from the literature (references in Table S1 in the supplemental material).

[b]C_{min}, minimum concentration of drug in serum.

were susceptible to all tested antibiotics according to the CLSI breakpoints, except for the ATCC 33591 methicillin-resistant *S. aureus* (MRSA) strain, which was resistant to doxycycline. For this reason, doxycycline was not used against ATCC 33591 biofilms for the next experiments. The MICs in cation-adjusted Mueller-Hinton broth (MHB-ca) and Trypticase soy broth (TSB) with 10 g/liter glucose and 20 g/liter NaCl (TGN) were within two dilutions of each other. Most of the MBECs exceeded the MICs by a hundred- or thousand-fold factor, to the notable exception of daptomycin, linezolid, and moxifloxacin against the strain ATCC 33591 in MHB-ca. The MBECs could not be established in TGN for the strain ATCC 47076, as we observed inconsistent results across replicates. All MBECs were found to be higher than the concentrations chosen for the coupon assays (Table 2).

Kinetics of TEC effect. The effect of TEC on ATCC 33591 MRSA biofilms is illustrated in Fig. 1 for CFU counts (Fig. 1A) and biomass (Fig. 1B and C). The CFU counts decreased modestly after 15 min of incubation ($-0.68\ \log_{10}$ CFU, $P = 0.0365$ from time zero), and no statistically significant differences were observed between the subsequent incubation times. A sharp decrease in the total biomass was observed after a 15-min incubation (-72.0% from time zero, $P = 3.3e-06$) and appeared to be maximal after 30 min (-95.82% from time zero, $P = 7.0e-07$; -19.45% from 15 min, $P = 0.014$). These effects were corroborated by macroscopic observation of the crystal violet-stained samples (Fig. 1C). Based on these results, an incubation time of 30 min with TEC was adopted for the next experiments.

Effect of individual enzymes compared to the TEC. In a preliminary experiment, the effect of the individual enzymes composing the TEC was tested against biofilms of each of the three species in comparison with the cocktail (Fig. 2). The TEC was found to be at least equivalent to the most effective single enzyme against all three species. While we did not observe any significant biofilm dispersal when treating methicillin-resistant *S. epidermidis* (MRSE) ATCC 35984 biofilms with the individual enzymes, exposure to the TEC resulted in a 93% reduction of the biomass ($P < 0.0001$). The RNA/DNA endonuclease was found to be equivalent to the TEC against MRSA ATCC 33591, and the β-1,6-hexosaminidase was equivalent to the TEC against *E. coli* ATCC 47076.

Effect of TEC and of antibiotics alone or in combination against biofilms. Biofilms exposed to TEC for 30 min were washed and reincubated in medium supplemented or not with antibiotics at clinically relevant concentrations (Table 2).

The results are illustrated in Fig. 3 (MRSA ATCC 33591), Fig. 4 (MRSE ATCC 35984), and Fig. 5 (*E. coli* ATCC 47076) for CFU counts (Fig. 3A, Fig. 4A, and Fig. 5A), biomass (Fig. 3B, Fig. 4B, and Fig. 5B), and fluorescence microscopy (Fig. 3C, Fig. 4C, and Fig.

FIG 1 Kinetics of biofilm dispersal by TEC against MRSA *S. aureus* ATCC 33591 biofilms. (A) Log_{10} CFU counts per coupon. (B) Total biomass assay (expressed as the percentage of time zero control). (C) Pictures of biofilm samples exposed to TEC for the indicated times (C-, negative control [coupon incubated in sterile culture medium]) stained with crystal violet. The values indicate the means of triplicate experiments ($\pm$ standard error). Statistical analysis, repeated measure ANOVA, followed by paired *t* tests with Holm correction. *, $P < 0.05$.

5C). The details of the comparisons are shown in Tables S2 to S7 in the supplemental material.

A 30-min exposure of the coupons to TEC significantly reduced the CFU counts and biomass of all strains. The CFU counts were reduced by 2.04 log_{10} in strain ATCC 33591, 2.54 log_{10} in strain ATCC 35984, and 1.24 log_{10} in strain ATCC 47076. Biomass was reduced by 95.2% in strain ATCC 33591, 88.6% in strain ATCC 35984, and 80.3% in strain ATCC 47076.

FIG 2 Effect of a 30-min treatment with the individual enzymes on the biomass of ATCC 33591, ATCC 35984, and ATCC 47076 biofilms and comparison to the TEC. Hexosaminidase, β-*N*-acetylhexosaminidase; endonuclease, DNA/RNA endonuclease; endoglucanase, endo-1,4-β-D-glucanase. Data expressed as percentage of the control. The values indicate the means of triplicate experiments ($\pm$ standard error). Statistical analysis, two-way ANOVA followed by Holm-Sidàk *post hoc* test. NS, no significant difference; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

**FIG 3** Effect of the combination of the TEC with antibiotics on MRSA ATCC 33591 biofilms. (A) CFU counts. (B) Biomass. (C) Fluorescence microscopy. (A and B) Blue, controls; red, samples treated for 30 min with TEC. T0, no reincubation; TGN, 24 h reincubation in TGN; others, 24 h reincubation in TGN with antibiotics at the indicated concentrations (see Table 1). CFU counts expressed in $\log_{10}$ CFU per coupon, and biomass expressed in percentage of T0 controls. The values indicate the means of triplicate experiments ($\pm$ standard error). Statistical analysis, two-way ANOVA followed by Tukey HSD comparing control samples to samples exposed to the enzymatic cocktail. NS, no significant difference; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$. (C) Green, living cells (SYTO 9); red, dead cells (propidium iodide). $\times 20$ magnification. Scale bars represent 50 μm. VAN, vancomycin; RIF, rifampin; LZD, linezolid; MXF, moxifloxacin; DAP, daptomycin.

A 24-h reincubation of control samples was not associated with significant changes in CFU counts. Their biomass remained stable in strains ATCC 35984 and ATCC 47076 but increased by 24.4% in strain ATCC 33591.

Similarly, the CFU counts of the samples treated with the enzyme cocktail and then reincubated for 24 h in TGN were similar to those of nontreated samples for all three strains. The biomass was however significantly lower than that for control group samples for ATCC 33591 (−19.1%) and ATCC 35984 (−34.7%) biofilms.

The effect of a 24-h exposure to antibiotics on control biofilms was variable versus CFU counts and generally weak or nonexistent versus the biomass when compared to initial controls (statistical analyses shown in Tables S2 to S7 in the supplemental material).

Against staphylococci, vancomycin (20 mg/liter) caused a 1.84 $\log_{10}$ CFU increase in the CFU counts of MRSE ATCC 35984 biofilms but no changes MRSA ATCC 33591. Conversely, the biomass of MRSA samples increased by 22.3% but did not change significantly in MRSE samples. Rifampin (2.5 mg/liter) caused a significant reduction of the CFU counts in both strains (ATCC 33591, −1.59 $\log_{10}$ CFU; ATCC 35984, −3.39 $\log_{10}$ CFU) but did not affect the biomass of either strain. Linezolid (5 mg/liter) had a limited effect on the CFU counts of strain ATCC 33591 (−1.50 $\log_{10}$) and did not affect the CFU counts of strain ATCC 35984 nor the biomass of both strains. Moxifloxacin (1.5 mg/liter)

FIG 4 Effect of the combination of the TEC with antibiotics on MRSE ATCC biofilms. (A) CFU counts. (B) Biomass. (C) Fluorescence microscopy. (A and B) Blue, controls; red, samples treated for 30 min with TEC. T0, no reincubation; TGN, 24 h reincubation in TGN; others, 24 h reincubation in TGN with antibiotics at the indicated concentrations (see Table 1). CFU counts expressed in $\log_{10}$ CFU per coupon, and biomass expressed in percentage of T0 controls. The values indicate the means of triplicate experiments ($\pm$ standard error). Statistical analysis, two-way ANOVA followed by Tukey HSD comparing control samples to samples exposed to the enzymatic cocktail. NS, no significant difference; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$. (C) Green, living cells (SYTO 9); red, dead cells (propidium iodide). $\times$20 magnification. Scale bars represent 50 μm. VAN, vancomycin; RIF, rifampin; LZD, linezolid; MXF, moxifloxacin; DAP, daptomycin; DOX, doxycycline.

impacted both strains differently despite similar MICs. In ATCC 33591 samples, the CFU counts did not change, and the biomass increased by 29.7%, while in ATCC 35984, a 2.52 $\log_{10}$ CFU decrease was observed and the biomass remained stable. Daptomycin (30 mg/liter) had a strong effect on the CFU counts of both strains (ATCC 33591, −4.99 $\log_{10}$; ATCC 35984, −3.50 $\log_{10}$) as well as a moderate effect on the biomass of strain 33591 (−20.2%), while the biomass of strain ATCC 35984 remained unchanged. Doxycycline (1.5 mg/liter) was used against MRSE ATCC 35984 only as MRSA ATCC 33591 was resistant. No significant effect was observed for either CFU counts or biomass.

Against *E. coli* ATCC 47076 biofilms, ceftazidime (3.8 mg/liter) and ciprofloxacin (1.625 mg/liter) had a significant effect on CFU counts (ceftazidime, −2.06 $\log_{10}$; ciprofloxacin, −3.21 $\log_{10}$) and biomass (ceftazidime, −61.7%; ciprofloxacin, −48.33%) while colistin (2.5 mg/liter) and meropenem (0.25 mg/liter) did not.

Turning now to the results for biofilms of the three strains successively exposed to TEC and antibiotics at set concentrations, we observed significant reductions of CFU counts and biomass compared to those of samples treated only with antibiotics, except for the CFU counts of MRSA ATCC 33591 samples treated with daptomycin (which were already markedly decreased by the antibiotic alone) and the biomass of *E. coli* ATCC 47076 treated with ceftazidime (for which the difference between samples

FIG 5 Effect of the combination of the TEC with antibiotics on *E. coli* ATCC 47076 biofilms. (A) CFU counts. (B) Biomass. (C) Fluorescence microscopy. (A and B) Blue, controls; red, samples treated for 30 min with TEC. T0, no reincubation; TGN, 24 h reincubation in TGN; others, 24 h reincubation in TGN with antibiotics at the indicated concentrations (see Table 1). CFU counts expressed in $\log_{10}$ CFU per coupon, biomass expressed in percentage of T0 controls. The values indicate the means of triplicate experiments ($\pm$ standard error). Statistical analysis, two-way ANOVA followed by Tukey HSD comparing control samples to samples exposed to the enzymatic cocktail. NS, no significant difference; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$. (C) Green, living cells (SYTO 9); red, dead cells (propidium iodide). $\times$20 magnification. Scale bars represent 50 μm. CEF, ceftazidime; CIP, ciprofloxacin; CST, colistin; MER, meropenem.

preexposed or not to the TEC cocktail did not reach significance). The difference in CFU counts between the samples preexposed to the enzymes and the control group samples was always higher than 2 $\log_{10}$ and exceeded 3 $\log_{10}$ in MRSA ATCC 33591 samples treated with vancomycin (-4.22 $\log_{10}$, $P < 0.0001$) or moxifloxacin (-3.87 $\log_{10}$, $P < 0.0001$), in MRSE ATCC 35984 samples treated with vancomycin (-6.84 $\log_{10}$, $P < 0.0001$), and in all *E. coli* ATCC 470476 samples exposed to any of the 4 tested antibiotics (ceftazidime, -5.23 $\log_{10}$, $P < 0.0001$); ciprofloxacin, -3.98 $\log_{10}$, $P < 0.0001$; colistin, -5.57 $\log_{10}$, $P < 0.0001$; meropenem, -6.11 $\log_{10}$, $P < 0.0001$).

The difference in biomass between samples treated with antibiotics alone or with the combination of TEC and antibiotics exceeded 80% in most conditions, except for strain ATCC 33591 samples treated with daptomycin and strain ATCC 47076 samples treated with ciprofloxacin and colistin.

The two-way analysis of variance (ANOVA) (Tables S8 to S13 in the supplemental material) showed significant interaction parameters in all cases when considering the exposure to the enzyme cocktail and the reincubation of the samples as factors. This suggests that the tri-enzyme cocktail and the antibiotics have a synergistic effect on both CFU counts and biomass of all three strains.

The analysis of biofilms using fluorescence microscopy after LIVE/DEAD staining

(Fig. 3C, Fig. 4C, and Fig. 5C) illustrates the observed CFU counts and biomass assays. The treatment of samples with the TEC dispersed an important proportion of the bacterial cells, which were enough to regrow a biofilm after 24 h of reincubation in TGN. This recovery appeared to be inhibited by the reincubation with antibiotics. The aspect of control samples exposed during 24 h to vancomycin, ciprofloxacin, and meropenem appeared unchanged from the samples incubated in TGN, keeping a majority of live cells (green), while the samples incubated with daptomycin exhibited a high proportion of dead cells (red).

Cytotoxicity tests. The cytotoxicity of the tri-enzyme cocktail for different types of eukaryotic cells was then evaluated by measuring the release of the cytosolic enzyme lactate dehydrogenase (LDH) in the culture medium after 1-h and 24-h exposures to TEC at two concentrations (concentration used against biofilms and a 1:1 dilution). At 1 h, no significant toxicity was detected (values of <5% in all cases). At 24 h, the release of the cytosolic enzyme lactate dehydrogenase (LDH) reached a mean percentage (95% confidence interval) of 3.0% (−1.1–7.0) for primary murine fibroblasts, −1.6% (−4.7–1.4) for MG-63 human osteosarcoma cells, and −3.2% (−17.0–10.7) for J774 murine macrophages.

DISCUSSION

This study found that a tri-enzymatic cocktail containing two glycoside hydrolases (an endo-1,4-β-D-glucanase and a β-1,6-hexosaminidase) and a nonspecific RNA/DNA endonuclease had a significant dispersal effect on mature biofilms of *S. aureus*, *S. epidermidis*, and *E. coli* reference strains grown on titanium alloy and that the successive treatment of these biofilms with this enzyme cocktail and antibiotics at concentrations relevant to the clinical setting was synergistic, resulting in significantly lower residual CFU counts than those with either individual treatment.

While the potential of glycoside hydrolases and DNase I as biofilm dispersal agents has been previously described in the literature (19, 22), the originality of our work resides in the association of enzymes targeting biofilm matrix components found in biofilms of varied species (30), which is hypothesized to help sidestep the limited spectrum of individual enzymes caused by the significant variations in matrix contents observed among bacterial species and strains (31, 32). Indeed, the results of individual enzyme assays performed in this study underline the added value of combining enzymes as was done in the TEC. The β-1,6-hexosaminidase used in this study is a dispersin B homolog targeting the poly-β-1,6-*N*-acetylglucosamine (PNAG) component of the biofilm matrix (33, 34). PNAG is an important constituent of the matrix of multiple species' biofilms and is required for the formation of biofilm by *S. epidermidis* (32, 35, 36) and *S. aureus* strains expressing the *icaABCD* operon (32, 37) and of *E. coli* strains expressing the *pgaABCD* locus (31, 38). Dispersin B was shown to disperse the biofilms of PNAG-producing strains of multiple species, including those included in our study (20, 39, 40). Cellulase is as endo-1,4-β-D-glucanase targeting cellulose, which is an important constituent of the biofilm matrix of *Enterobacter* spp. (41), including *E. coli* (42). It has been shown to disperse *E. coli* (27) and *Pseudomonas aeruginosa* (21) biofilms *in vitro*. The recombinant nonspecific endonuclease targets both DNA and RNA phosphodiester bonds (43). DNA is a common component of the biofilm matrix of most bacterial species, including *S. aureus*, *S. epidermidis*, and *E. coli* (44). While the biofilm dispersal properties of this enzyme had not been previously investigated, it has been favorably compared to the widely studied DNase I (22) for the hydrolysis of DNA in sputum (45).

The dispersal of biofilms by enzymes similar to the ones constituting TEC was shown in previous publications to reduce the tolerance of bacterial biofilms to antibiotics (21, 25, 46) and antiseptics (27). However, limitations related to the use of single enzymes have been reported. Izano et al. (39) observed that DNase I did not disperse biofilms of *S. epidermidis* contrarily to *S. aureus* and that dispersin B had an inverse effect by dispersing *S. epidermidis* biofilms and leaving *S. aureus* biofilms intact. Accordingly, they found that the dispersal of these biofilms by the appropriate enzyme

(DNase I for *S. aureus* of dispersin B for *S. epidermidis*) improved the effect of the detergent cetylpyridinium chloride on CFU counts (39).

Our results illustrate the broad spectrum of the tri-enzymatic cocktail, which stems from the combination of enzymes with different activity spectrums (30). Furthermore, these results support the hypothesis of a synergy of enzymatic dispersal and a broad selection of antibiotics at concentrations clinically relevant to the treatment of PJIs against biofilms. As could be expected from the observed MBEC values, the antibiotic concentrations used for the coupon assays had a minimal effect on control biofilms, but their combination with an enzymatic pretreatment resulted in significant reductions of culturable cell numbers as well as total biomass in nearly all combinations of bacterial species and antibiotics.

The cytotoxicity of TEC to different cell lines relevant to the joint environment (macrophages, fibroblasts, osteoblasts) was found to be negligible after a 24-h exposure. An explanation to this observation could be that the targets of these enzymes are either not produced by mammalian cells (cellulose) or irrelevant to their proliferation (eDNA and PNAG).

These results should however be interpreted with caution, as our study presents some limitations. We limited ourselves to the study of biofilms of reference strains. While this facilitates the replication of our results by other teams in comparison to clinical strains, the loss of diversity in gene expression could mask the effect of the variability in matrix composition observed in some species (47). The antibiotic concentrations considered in our study did not take into account the serum protein binding. Among the drugs used in this study, doxycycline and daptomycin show a high serum protein binding, which could lead to an overestimation of their effects in our experimental setting. However, the albumin concentration in synovial fluid is three to four times inferior to the serum concentration (48). This difference in albumin concentrations could lead to a higher free fraction of drugs in the synovial fluid than in serum. For this reason, the total serum concentration appeared to be a reasonable estimate that limited the risk of underestimating the effects of antibiotics. The *in vitro* nature of our experiments limits extrapolation to the clinical setting, as it does not represent the diversity of the situations encountered in a clinical setting nor does the use of set concentrations of antibiotics reproduce the complex pharmacokinetics observed in the bone and joint environment (49).

However, these observations support our hypothesis that a treatment approach combining local administration, such as an intraarticular injection, of a broad-spectrum enzymatic cocktail and antibiotics could prove to be beneficial in a PJI setting where the variety of pathological bacterial species encountered is important (3). Further studies in more refined models, such as animal PJI models, should therefore be undertaken to confirm our *in vitro* results and determine an adequate strategy around this approach in complement to DAIR.

MATERIALS AND METHODS

Bacterial strains, antibiotics, and enzymes. (i) Strains. Methicillin-resistant *Staphylococcus aureus* ATCC 33591, methicillin-resistant *Staphylococcus epidermidis* ATCC 35984, and *Escherichia coli* ATCC 47076 were used as representatives of the bacterial species usually encountered in PJI.

(ii) Antibiotics. The following antibiotics were used as laboratory standards: ciprofloxacin HCl (potency, 93.9%) and moxifloxacin HCl (potency, 90.9%) from Bayer AG (Leverkusen, Germany); colistin (potency, 79.6%) and doxycycline (potency, 90.2%) from Sigma-Aldrich (Saint-Louis, MO, USA); and linezolid (potency, 99.2%) from RibX Pharmaceuticals (Morristown, NJ, USA). The following antibiotics were used as powders for injections in humans: ceftazidime (potency, 72.5%; Panpharma France, Luitré, France), daptomycin (potency, 100%; MSD, Puteaux, France), meropenem (potency, 92%; Hospira Benelux BVBA, Brussels, Belgium), rifampin (potency, 100%; Aventis, Schiltigheim, France), and vancomycin (potency, 97.5%; Mylan, Hoeilaart, Belgium). The antibiotic concentrations were set on the basis of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of the antibiotics studied and their pharmacokinetic parameters in humans described in the EUCAST rationales for clinical breakpoints or in the literature (Table 2).

(iii) Tri-enzymatic cocktail. The tri-enzymatic cocktail (TEC; OrthenzyQure) used in this study was designed and provided by OneLife SA (Louvain-la-Neuve, Belgium). It consists of a sterile Tris-buffered (pH = 7) aqueous solution containing 400 U/ml of aspecific DNA/RNA endonuclease from *Serratia*

marcescens (c-LEcta GmbH, Leipzig, Germany), 50 U/ml of endo-1,4-β-D-glucanase from *Aspergillus niger* (Sigma), and 0.06 U/ml of β-N-acetylhexosaminidase from *Actinobacillus pleuropneumoniae* (GIGA, Liège, Belgium) (composition described in patent publication numbers WO2017/211737 [28] and BE2020/5726 [29]). The TEC was stored at 4°C and was heated at 37°C for 30 min before use. The TEC is available upon request at OneLife SA for research purposes (under R&D reference OL-RD1000/OrthenzyQure).

In order to assay the biofilm dispersal effect of the individual enzymes, OneLife provided solutions of the individual enzymes at concentrations identical to those used in the TEC.

Susceptibility testing. MICs were determined by microdilution following the CLSI protocol (50) in MHB-ca and TGN (TSB + 2% NaCl + 1% glucose), i.e., the medium used for growing biofilms. MICs of daptomycin were tested in MHB-ca and TGN containing 50 mg/liter of Ca^{2+}.

MBECs were assayed by growing biofilms in Calgary biofilm devices (CBD; Innovotech, Edmonton, Canada) in MHB-ca and TGN. Bacterial suspensions were prepared in phosphate-buffered saline (PBS), starting from overnight cultures on Trypticase soy agar (TSA) from frozen stocks. The suspensions were adjusted to a turbidity of 0.5 McFarland and diluted 1:10 in medium. A total of 150 μl was added per well of the CBDs. The CBDs were incubated for 24 h at 37°C under a continuous rotation of 50 rpm to allow biofilm formation. Antibiotic dilutions in the two media—with 50 mg/liter of Ca^{2+} when assaying daptomycin—were prepared in new 96-well plates at concentrations ranging from 1,024 mg/liter to 0.5 mg/liter (256 mg/liter to 0.125 mg/liter for meropenem). The lids of the CBDs were rinsed twice in PBS before being transferred to the plates containing the antibiotics. The plates were then incubated for 24 h at 37°C with a continuous rotation of 50 rpm. At the end of the antibiotic challenge, the lids were rinsed twice in PBS before being transferred to new plates containing plain medium. The plates were then sonicated for 10 min (Branson 5510 ultrasonic bath; Emerson Electric, Saint-Louis, MO, USA). New sterile lids were placed, and the plates were incubated for 24 h at 37°C without agitation. At the end of the incubation period, the plates were examined for bacterial growth, and optical density measures at 650 nm (OD_{650}) were performed using a SpectraMax M3 spectrophotometer (Molecular Devices, San Jose, CA, USA).

Biofilm culture. Bacterial suspensions were prepared in PBS, starting from overnight cultures on TSA from frozen stocks. The suspensions were adjusted to an OD_{620} of 0.5 (~8.5 $\log_{10}$ CFU/ml) using a CECIL 2021 spectrophotometer (Cecil Instruments Ltd, Milton, United-Kingdom). The suspension was then diluted 1:100 in TGN. The biofilms were grown on titanium alloy (Ti-6Al-4V) coupons (BioSurface, Bozeman, MN, USA) in 12-well plates using 3 ml of the final suspension per coupon. The plates were incubated for 24 h (ATCC 33591 and ATCC 35984) or 48 h (ATCC 47076) at 37°C, with a constant orbital shaking of 50 rpm. In the case of strain ATCC 47076 biofilms, the medium was changed after 24 h. These culture times were selected, as they allowed the biofilms to reach steady state over the study period and were determined in previous growth kinetic experiments for *S. aureus* (14). The culture duration period for *S. epidermidis* was derived from these results. Growth kinetic experiments were performed in this study for *E. coli* biofilms and showed that a steady state was reached after 48 h of culture. Samples were analyzed for CFU counts and biomass every 24 h for the growth kinetic experiments.

Biofilm treatments. (i) Individual enzyme assays. The biofilm samples were rinsed twice with sterile PBS. They were then transferred to 24-well plates filled with either 1 ml of TEC or 1 ml of one of the individual enzymes at 37°C. The plates were then incubated for 30 min at 37°C. At the end of the incubation period, the biofilms were rinsed twice in sterile PBS and assayed for total biomass (see below).

(ii) Combination of enzymatic cocktail and antibiotics. The biofilm samples were separated into a control group and an enzyme cocktail group. The coupons of both groups were rinsed twice in sterile PBS before being submitted to the treatments. The tri-enzyme cocktail group samples were transferred to a 24-well plate, in which the wells were previously filled with 1 ml of enzyme cocktail at 37°C. The plates were then incubated at 37°C with no agitation for either 15, 30, and 60 min (when studying the kinetics of activity) or 30 min (other experiments). After incubation, the samples were rinsed twice in sterile PBS before either immediate analysis (see below for analysis technique descriptions) or reincubation. Control group samples were directly rinsed in sterile PBS. All samples were then reincubated for 24 h at 37°C under a constant orbital shaking of 50 rpm in TGN or TGN containing antibiotics at set concentrations (TGN + 50 mg/liter of Ca^{2+} for samples exposed to daptomycin) (see Table 2) in 12-well plates containing 3 ml of medium per well.

Biofilms analysis. The coupons were rinsed twice in sterile PBS and then analyzed using the following techniques.

(i) CFU counts. Coupons were placed in 15-ml conical tubes (Greiner Bio-One International GmbH, Kremsmünster, Austria) filled with 2 ml of sterile PBS. In order to detach the biofilms and suspend the bacteria, the tubes were then vortexed for 30 s at maximum intensity (Vortex-Genie 2; Scientific Industries, Inc., Bohemia, NY, USA), sonicated for 5 min (Branson 5510 Ultrasonic bath, Emerson Electric, Saint-Louis, MO, USA), and vortexed again for 30 s. The suspension was then sampled and serially diluted before plating on TSA. The TSA plates were then incubated for 24 to 48 h at 37°C until the colonies reached an adequate size. CFU counts were then obtained using an automated method (image acquisition using Gel Doc XR+ and image processing using Quantity One (Bio-Rad, Hercules, CA, USA).

(ii) Biomass assay. Coupons were dried overnight at 60°C. They were then stained with 1 ml of 1% crystal violet solution for 10 min (Sigma-Aldrich Corp.). The coupons were then rinsed twice using deionized water to remove the excess dye. Afterward, they were placed for 1 h in 24-well plates filled with 1 ml of 66% acetic acid solution (Merck KGaA, Darmstadt, Germany) to resolubilize the dye. The coupons were removed from the wells, and the absorbance of the solution was read at 570 nm using a SpectraMax M3 spectrophotometer (Molecular Devices, San Jose, CA, USA).

(iii) Fluorescence microscopy. Coupons were rinsed twice in sterile deionized water to avoid

interference from phosphate ions. They were then stained using the Filmtracer LIVE/DEAD biofilm viability kit (Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer's instructions. Coupons were then rinsed again twice in sterile deionized water before imaging using an Axio Imager Z1 microscope fitted with an ApoTome 1 attachment (Zeiss, Oberkochen, Germany) at a $\times 20$ magnification. The images were postprocessed using FIJI (51, 52), using the maximum intensity projection technique, and by adjusting the brightness of the channels.

Cytotoxicity assays. (i) Cell culture. J774 murine macrophages (Sandoz Forschung Laboratories, Vienna, Austria) (53), MG-63 human osteoblasts (ATCC CRL-1427), and primary murine fibroblasts (54) were used for the cytotoxicity assays. The cells were grown in RPMI 1640 or Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (all products from Thermo Fisher Scientific Inc., Waltham, MA, USA) at 37°C in a 5% CO_2 atmosphere. The cells were used for the assays between passages 2 and 5.

The cells were cultured initially in 250-cm^3 cell culture flasks before being transferred to 96-well plates at a concentration of 10^4 cells per well. The plates were incubated for 24 h at 37°C with 5% CO_2 to allow cellular adhesion to the wells before testing.

(ii) Assay. Cytotoxicity was assessed by measuring the release of the cytoplasmic enzyme lactate dehydrogenase (LDH) in the culture medium, using the cytotoxicity detection kit (Sigma-Aldrich). The wells were rinsed with sterile PBS before adding 100 μl of medium with 1% decomplemented fetal bovine serum. A total of 100 μl of the following test substances were then added to the wells (final concentrations): TEC (concentration used against biofilms and half of this concentration), Triton X-100 solution (1%, positive control), medium with 1% decomplemented serum (negative control). Three empty wells per experiment were filled with 200 μl of medium with 1% decomplemented serum to measure the background signal.

The plates were then incubated for 1 h or 24 h at 37°C in a 5% CO_2 atmosphere. A total of 100 μl of the supernatant of each well was aspirated and transferred to a new 96-well plate and added by 100 μl of the extemporaneously prepared LDH assay solution as per the manufacturer's instructions. The plates were then incubated for 30 min at room temperature in the dark. The light absorbance was then measured at 490 nm and 650 nm using a SpectraMax M3 spectrophotometer (Molecular Devices, San Jose, CA, USA).

Data transformation and statistical analysis. CFU counts were normalized using a base 10 logarithmic transformation before analysis. Absorbance values of the biomass assays were transformed into percentages of the T0 (no reincubation) controls after subtracting the average value of negative controls. The absorbance values of the LDH assays were transformed into percentages using the following equation:

$$\text{Cytotoxicity}\,(\%) = \frac{\text{Abs. exp. value}_{420nm-650nm} - \text{Abs. control}\,(-)_{420nm-650nm}}{\text{Abs. control}\,(+)_{420nm-650nm} - \text{Abs. control}\,(-)_{420nm-650nm}} \times 100$$

The statistical analysis was then performed using R (version 3.6.1) and the package car (version 3.0.6) or in GraphPad 8.4.3 (GraphPad Software, San Diego, CA). The TEC kinetics experiment data were analyzed using repeated measures ANOVA followed by paired t tests with Holm correction. The data relating to the combined effect of TEC and antibiotics were analyzed using two-way ANOVA after assessing the normality of residues with QQ plots and the equality of variances using the Levene test. The Tukey honestly significant difference (HSD) test was used to perform pairwise comparisons. The synergy of treatments was defined as a statistically significant interaction parameter of the two-way ANOVAs (55). The threshold for alpha errors is 0.05. The data reported in the text are the means with 95% confidence interval.

Data availability. The data for the experiments reported in this publication are available upon request to the corresponding author.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.

REFERENCES

1. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. 2012. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 27:61–65. https://doi.org/10.1016/j.arth.2012.02.022.

2. Bozic KJ, Kamath AF, Ong K, Lau E, Kurtz S, Chan V, Vail TP, Rubash H, Berry DJ. 2015. Comparative epidemiology of revision arthroplasty: failed THA poses greater clinical and economic burdens than failed TKA. Clin Orthop Relat Res 473:2131–2138. https://doi.org/10.1007/s11999-014-4078-8.

3. Aggarwal VK, Bakhshi H, Ecker NU, Parvizi J, Gehrke T, Kendoff D. 2014. Organism profile in periprosthetic joint infection: pathogens differ at two arthroplasty infection referral centers in Europe and in the United States. J Knee Surg 27:399–406. https://doi.org/10.1055/s-0033-1364102.

4. Arciola CR, Campoccia D, Montanaro L. 2018. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol 16:397–409. https://doi.org/10.1038/s41579-018-0019-y.

5. Stewart PS. 2015. Antimicrobial tolerance in biofilms. Microbiol Spectr 3:MB-0010-2014. https://doi.org/10.1128/microbiolspec.MB-0010-2014.

6. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771–1776. https://doi.org/10.1128/JCM.37.6.1771-1776.1999.

7. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR, Infectious Diseases Society of America. 2013. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 56:e1–e25. https://doi.org/10.1093/cid/cis803.

8. Grammatopoulos G, Bolduc ME, Atkins BL, Kendrick BJL, McLardy-Smith P, Murray DW, Gundle R, Taylor AH. 2017. Functional outcome of debridement, antibiotics and implant retention in periprosthetic joint infection involving the hip: a case-control study. Bone Joint J 99-B:614–622. https://doi.org/10.1302/0301-620X.99B5.BJJ-2016-0562.R2.

9. Peel TN, Dowsey MM, Buising KL, Liew D, Choong PFM. 2013. Cost analysis of debridement and retention for management of prosthetic joint infection. Clin Microbiol Infect 19:181–186. https://doi.org/10.1111/j.1469-0691.2011.03758.x.

10. Klouche S, Sariali E, Mamoudy P. 2010. Total hip arthroplasty revision due to infection: a cost analysis approach. Orthop Traumatol Surg Res 96:124–132. https://doi.org/10.1016/j.otsr.2009.11.004.

11. Urish KL, Bullock AG, Kreger AM, Shah NB, Jeong K, Rothenberger SD, Infected Implant Consortium. 2018. A multicenter study of irrigation and debridement in total knee arthroplasty periprosthetic joint infection: treatment failure is high. J Arthroplasty 33:1154–1159. https://doi.org/10.1016/j.arth.2017.11.029.

12. Kunutsor SK, Beswick AD, Whitehouse MR, Wylde V, Blom AW. 2018. Debridement, antibiotics and implant retention for periprosthetic joint infections: a systematic review and meta-analysis of treatment outcomes. J Infect 77:479–488. https://doi.org/10.1016/j.jinf.2018.08.017.

13. Urish KL, DeMuth PW, Craft DW, Haider H, Davis CM, III. 2014. Pulse lavage is inadequate at removal of biofilm from the surface of total knee arthroplasty materials. J Arthroplasty 29:1128–1132. https://doi.org/10.1016/j.arth.2013.12.012.

14. Poilvache H, Ruiz-Sorribas A, Sakoulas G, Rodriguez-Villalobos H, Cornu O, Van Bambeke F. 2020. Synergistic effects of pulsed lavage and antimicrobial therapy against Staphylococcus aureus biofilms in an in-vitro model. Front Med (Lausanne) 7:527. https://doi.org/10.3389/fmed.2020.00527.

15. Moriarty TF, Kuehl R, Coenye T, Metsemakers WJ, Morgenstern M, Schwarz EM, Riool M, Zaat SAJ, Khana N, Kates SL, Richards RG. 2016. Orthopaedic device-related infection: current and future interventions for improved prevention and treatment. EFORT Open Rev 1:89–99. https://doi.org/10.1302/2058-5241.1.000037.

16. Stoodley P, Ehrlich GD, Sedghizadeh PP, Hall-Stoodley L, Baratz ME, Altman DT, Sotereanos NG, Costerton JW, Demeo P. 2011. Orthopaedic biofilm infections. Curr Orthop Pract 22:558–563. https://doi.org/10.1097/BCO.0b013e318230efcf.

17. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. 2012. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 33:5967–5982. https://doi.org/10.1016/j.biomaterials.2012.05.031.

18. Romano CL, Toscano M, Romano D, Drago L. 2013. Antibiofilm agents and implant-related infections in orthopaedics: where are we? J Chemother 25:67–80. https://doi.org/10.1179/1973947812Y.0000000045.

19. Vuotto C, Donelli G. 2019. Novel treatment strategies for biofilm-based infections. Drugs 79:1635–1655. https://doi.org/10.1007/s40265-019-01184-z.

20. Kaplan JB, Ragunath C, Velliyagounder K, Fine DH, Ramasubbu N. 2004. Enzymatic detachment of Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 48:2633–2636. https://doi.org/10.1128/AAC.48.7.2633-2636.2004.

21. Fleming D, Chahin L, Rumbaugh K. 2017. Glycoside hydrolases degrade polymicrobial bacterial biofilms in wounds. Antimicrob Agents Chemother 61:e01998-16. https://doi.org/10.1128/AAC.01998-16.

22. Fleming D, Rumbaugh KP. 2017. Approaches to dispersing medical biofilms. Microorganisms 5:15. https://doi.org/10.3390/microorganisms5020015.

23. Tetz GV, Artemenko NK, Tetz VV. 2009. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother 53:1204–1209. https://doi.org/10.1128/AAC.00471-08.

24. Hogan S, Zapotoczna M, Stevens NT, Humphreys H, O'Gara JP, O'Neill E. 2017. Potential use of targeted enzymatic agents in the treatment of Staphylococcus aureus biofilm-related infections. J Hosp Infect 96:177–182. https://doi.org/10.1016/j.jhin.2017.02.008.

25. Kaplan JB, LoVetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, Izano EA. 2012. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 65:73–77. https://doi.org/10.1038/ja.2011.113.

26. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. 2009. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother 64:88–93. https://doi.org/10.1093/jac/dkp158.

27. Lim ES, Koo OK, Kim MJ, Kim JS. 2019. Bio-enzymes for inhibition and elimination of Escherichia coli O157:H7 biofilm and their synergistic effect with sodium hypochlorite. Sci Rep 9:9920. https://doi.org/10.1038/s41598-019-46363-w.

28. Siala MW, Vanzieleghem MT. 14 December 2017. Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections. International patent WO2017/211737A1.

29. Fontaine L, Lardinois A, Chalhoub H. 16 October 2020. Composition para-pharmaceutique ou pharmaceutique administrable à un être vivant, de préférence un être humain, comprenant au moins une enzyme pour le traitement et/ou la prévention d'infections bactériennes impliquant la formation de biofilm. Patent BE2020/5726.

30. Siala W, Hoche A, Van Bambeke F, Vanzieleghem T. 2018. Activity of combinations of an enzymatic cocktail (CDD) with antibiotics against biofilms of clinical isolates of ESKAPE pathogens, abstr. 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 21 to 24 April 2018.

31. Horvat M, Pannuri A, Romeo T, Dogsa I, Stopar D. 2019. Viscoelastic response of Escherichia coli biofilms to genetically altered expression of extracellular matrix components. Soft Matter 15:5042–5051. https://doi.org/10.1039/c9sm00297a.

32. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, Scherpe S, Davies AP, Harris LG, Horstkotte MA, Knobloch JKM, Ragunath C, Kaplan JB, Mack D. 2007. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections. Biomaterials 28:1711–1720. https://doi.org/10.1016/j.biomaterials.2006.11.046.

33. Kaplan JB, Ragunath C, Ramasubbu N, Fine DH. 2003. Detachment of Actinobacillus actinomycetemcomitans biofilm cells by an endogenous beta-hexosaminidase activity. J Bacteriol 185:4693–4698. https://doi.org/10.1128/jb.185.16.4693-4698.2003.

34. Kaplan JB, Velliyagounder K, Ragunath C, Rohde H, Mack D, Knobloch JKM, Ramasubbu N. 2004. Genes involved in the synthesis and degradation of matrix polysaccharide in Actinobacillus actinomycetemcomitans and

Actinobacillus pleuropneumoniae biofilms. J Bacteriol 186:8213–8220. https://doi.org/10.1128/JB.186.24.8213-8220.2004.

35. Mack D, Fischer W, Krokotsch A, Leopold K, Hartmann R, Egge H, Laufs R. 1996. The intercellular adhesin involved in biofilm accumulation of Staphylococcus epidermidis is a linear beta-1,6-linked glucosaminoglycan: purification and structural analysis. J Bacteriology 178:175–183. https://doi.org/10.1128/JB.178.1.175-183.1996.

36. Post V, Harris LG, Morgenstern M, Mageiros L, Hitchings MD, Meric G, Pascoe B, Sheppard SK, Richards RG, Moriarty TF. 2017. Comparative genomics study of Staphylococcus epidermidis isolates from orthopedic-device-related infections correlated with patient outcome. J Clin Microbiol 55:3089–3103. https://doi.org/10.1128/JCM.00881-17.

37. Gowrishankar S, Kamaladevi A, Balamurugan K, Pandian SK. 2016. In vitro and in vivo biofilm characterization of methicillin-resistant Staphylococcus aureus from patients associated with pharyngitis infection. Biomed Res Int 2016:1289157. https://doi.org/10.1155/2016/1289157.

38. Wang X, Preston JF, III, Romeo T. 2004. The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J Bacteriol 186:2724–2734. https://doi.org/10.1128/jb.186.9.2724-2734.2004.

39. Izano EA, Amarante MA, Kher WB, Kaplan JB. 2008. Differential roles of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in Staphylococcus aureus and Staphylococcus epidermidis biofilms. Appl Environ Microbiol 74:470–476. https://doi.org/10.1128/AEM.02073-07.

40. Itoh Y, Wang X, Hinnebusch BJ, Preston JF, III, Romeo T. 2005. Depolymerization of beta-1,6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. J Bacteriol 187:382–387. https://doi.org/10.1128/JB.187.1.382-387.2005.

41. Zogaj X, Bokranz W, Nimtz M, Römling U. 2003. Production of cellulose and curli fimbriae by members of the family Enterobacteriaceae isolated from the human gastrointestinal tract. Infect Immun 71:4151–4158. https://doi.org/10.1128/iai.71.7.4151-4158.2003.

42. Zogaj X, Nimtz M, Rohde M, Bokranz W, Romling U. 2001. The multicellular morphotypes of Salmonella typhimurium and Escherichia coli produce cellulose as the second component of the extracellular matrix. Mol Microbiol 39:1452–1463. https://doi.org/10.1046/j.1365-2958.2001.02337.x.

43. Nestle M, Roberts WK. 1969. An extracellular nuclease from Serratia marcescens. I. Purification and some properties of the enzyme. J Biol Chem 244:5213–5218. https://doi.org/10.1016/S0021-9258(18)63648-8.

44. Jakubovics NS, Shields RC, Rajarajan N, Burgess JG. 2013. Life after death: the critical role of extracellular DNA in microbial biofilms. Lett Appl Microbiol 57:467–475. https://doi.org/10.1111/lam.12134.

45. Vafina G, Zainutdinova E, Bulatov E, Filimonova MN. 2018. Endonuclease from Gram-negative bacteria Serratia marcescens is as effective as Pulmozyme in the hydrolysis of DNA in sputum. Front Pharmacol 9:114. https://doi.org/10.3389/fphar.2018.00114.

46. Waryah CB, Wells K, Ulluwishewa D, Chen-Tan N, Gogoi-Tiwari J, Ravensdale J, Costantino P, Gökçen A, Vilcinskas A, Wiesner J, Mukkur T. 2017. In vitro antimicrobial efficacy of tobramycin against Staphylococcus aureus biofilms in combination with or without DNase I and/or dispersin B: a preliminary investigation. Microb Drug Resist 23:384–390. https://doi.org/10.1089/mdr.2016.0100.

47. O'Gara JP. 2007. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett 270:179–188. https://doi.org/10.1111/j.1574-6968.2007.00688.x.

48. Levick JR. 1981. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 24:1550–1560. https://doi.org/10.1002/art.1780241215.

49. Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. 2009. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 48:89–124. https://doi.org/10.2165/00003088-200948020-00002.

50. Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. CLSI M100. Clinical and Laboratory Standards Institute, Wayne, PA.

51. Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW. 2017. ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 18:529. https://doi.org/10.1186/s12859-017-1934-z.

52. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019.

53. Snyderman R, Pike MC, Fischer DG, Koren HS. 1977. Biologic and biochemical activities of continuous macrophage cell lines P388D1 and J774.1. J Immunol 119:2060–2066.

54. Tulkens P, Beaufay H, Trouet A. 1974. Analytical fractionation of homogenates from cultured rat embryo fibroblasts. J Cell Biol 63:383–401. https://doi.org/10.1083/jcb.63.2.383.

55. Slinker BK. 1998. The statistics of synergism. J Mol Cell Cardiol 30:723–731. https://doi.org/10.1006/jmcc.1998.0655.

Supplemental materials

1 References for antibiotic concentrations rationales

Table 1. Antibiotics experimental concentrations and rationales.

Antibiotic	Concentration (mg/L)	Rationale	References
Daptomycin (DAP)	30	$\frac{AUC_{0-24h}}{24h}$	European Committee on Antimicrobial Susceptibility Testing. (2005a). Daptomycin: Rationale for the EUCAST clinical breakpoints, version 1.0. In: http://www.eucast.org. Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003). Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. *Antimicrob Agents Chemother, 47*(4), 1318-1323. doi:10.1128/aac.47.4.1318-1323.2003
Doxycycline (DOX)	1.5	$\frac{AUC_{0-24h}}{24h}$	European Committee on Antimicrobial Susceptibility Testing. (2009a). Doxycycline: Rationale for the EUCAST clinical breakpoints, version 1.0. In: http://www.eucast.org.
Linezolid (LZD)	5	C_{min}	European Committee on Antimicrobial Susceptibility Testing. (2005b). Linezolid: Rationale for the EUCAST clinical breakpoints, version 1.0. In: http://www.eucast.org.
Moxifloxacin (MXF)	1.5	$\frac{AUC_{0-24h}}{24h}$	European Committee on Antimicrobial Susceptibility Testing. (2007b). Moxifloxacin: Rationale for the EUCAST clinical breakpoints, version 2.3. In: http://www.eucast.org.
Rifampin (RIF)	2.5	$\frac{AUC_{0-24h}}{24h}$	European Committee on Antimicrobial Susceptibility Testing. (2010b). Rifampicin: Rationale for the EUCAST clinical breakpoints, version 1.0. In: http://www.eucast.org.
Vancomycin (VAN)	2	Target trough concentration (20 mg/L)	European Committee on Antimicrobial Susceptibility Testing. (2010c). Vancomycin: Rationale for the EUCAST clinical breakpoints, version 2.1. In: http://www.eucast.org. Osmon, D. R., Berbari, E. F., Berendt, A. R., Lew, D., Zimmerli, W., Steckelberg, J. M., . . . Infectious Diseases Society of, A. (2013). Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases

			Society of America. *Clin Infect Dis, 56*(1), e1-e25. doi:10.1093/cid/cis803
			European Committee on Antimicrobial Susceptibility Testing. (2010). Ceftazidime: Rationale for the EUCAST clinical breakpoints, version 1.0. In: http://www.eucast.org.
Ceftazidime (CEF)	3.8	C_{min}	Luthy, R., Blaser, J., Bonetti, A., Simmen, H., Wise, R., & Siegenthaler, W. (1981). Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. *Antimicrob Agents Chemother, 20*(5), 567-575. doi:10.1128/aac.20.5.567
Ciprofloxacin (CIP)	1.625	$\dfrac{AUC_{0-24h}}{24h}$	European Committee on Antimicrobial Susceptibility Testing. (2007a). Ciprofloxacin: Rationale for the EUCAST clinical breakpoints, version 1.9. In: http://www.eucast.org.
Colistin (CST)	2.5	$\dfrac{AUC_{0-24h}}{24h}$	European Committee on Antimicrobial Susceptibility Testing. (2010a). Colistin: Rationale for the EUCAST clinical breakpoints, version 1.0. In: http://www.eucast.org.
Meropenem (MEM)	0.25	C_{min}	European Committee on Antimicrobial Susceptibility Testing. (2009b). Meropenem: Rationale for the EUCAST clinical breakpoints, version 1.5. In: http://www.eucast.org.

2 Selected post-hoc comparisons

Table 2. ATCC 33591 (MRSA). Log$_{10}$ CFU counts. Tukey HSD results.

Comparisons	Differences	95% confidence intervals		Adjusted p values	
		Lower	Upper		
CDD:T0-Control:T0	-2.04	-3.25	-0.83	0.00004	****
Control:TGN-Control:T0	0.67	-0.54	1.88	0.78924	NS
CDD:TGN-Control:T0	0.56	-0.65	1.77	0.93022	NS
Control:VAN 20-Control:T0	0.90	-0.40	2.21	0.46604	NS
CDD:VAN 20-Control:T0	-3.32	-4.63	-2.02	0.00000	****
Control:RIF 2.5-Control:T0	-1.59	-2.89	-0.28	0.00620	**
CDD:RIF 2.5-Control:T0	-3.42	-4.73	-2.12	0.00000	****
Control:LIN 5-Control:T0	-1.50	-2.81	-0.20	0.01196	*
CDD:LIN 5-Control:T0	-4.02	-5.32	-2.71	0.00000	****
Control:MXF 1.5-Control:T0	-0.31	-1.62	0.99	0.99992	NS
CDD:MXF 1.5-Control:T0	-4.18	-5.48	-2.87	0.00000	****
Control:DAP 30-Control:T0	-4.99	-6.30	-3.69	0.00000	****
CDD:DAP 30-Control:T0	-6.05	-7.36	-4.75	0.00000	****
CDD:TGN-Control:TGN	-0.11	-1.32	1.10	1.00000	NS
CDD:VAN 20-Control:VAN 20	-4.22	-5.62	-2.83	0.00000	****
CDD:RIF 2.5-Control:RIF 2.5	-1.83	-3.23	-0.44	0.00223	**
CDD:LIN 5-Control:LIN 5	-2.51	-3.91	-1.12	0.00001	****
CDD:MXF 1.5-Control:MXF 1.5	-3.87	-5.26	-2.47	0.00000	****
CDD:DAP 30-Control:DAP 30	-1.06	-2.45	0.34	0.31803	NS

Table 3. ATCC 33591 (MRSA). Biomass assay (% of T0 control). Tukey HSD results.

Comparisons	Differences	95% confidence intervals		Adjusted p values	
		Lower	Upper		
CDD:T0-Control:T0	-95.2	-113.7	-76.6	0	****
Control:TGN-Control:T0	24.4	5.9	43.0	0.00213	***
CDD:TGN-Control:T0	5.3	-13.3	23.9	0.99933	NS
Control:VAN 20-Control:T0	22.2	2.2	42.3	0.01804	*
CDD:VAN 20-Control:T0	-89.6	-109.7	-69.5	0	****
Control:RIF 2.5-Control:T0	7.8	-12.3	27.8	0.98545	NS
CDD:RIF 2.5-Control:T0	-88.6	-108.6	-68.5	0.00000	****
Control:LIN 5-Control:T0	13.3	-6.8	33.4	0.53801	NS
CDD:LIN 5-Control:T0	-95.4	-115.5	-75.4	0.00000	****
Control:MXF 1.5-Control:T0	21.8	1.7	41.8	0.02281	*
CDD:MXF 1.5-Control:T0	-85.8	-105.9	-65.7	0.00000	****
Control:DAP 30-Control:T0	-20.2	-38.8	-1.6	0.02187	*
CDD:DAP 30-Control:T0	-87.7	-106.3	-69.1	0.00000	****
CDD:TGN-Control:TGN	-19.1	-37.7	-0.5	0.03864	*
CDD:VAN 20-Control:VAN 20	-111.8	-133.3	-90.4	0	****
CDD:RIF 2.5-Control:RIF 2.5	-96.3	-117.8	-74.9	0	****
CDD:LIN 5-Control:LIN 5	-108.8	-130.2	-87.3	0	****
CDD:MXF 1.5-Control:MXF 1.5	-107.5	-129.0	-86.1	0	****
CDD:DAP 30-Control:DAP 30	-67.5	-86.0	-48.9	0	****

Table 4. ATCC 35984 (MRSE). Log$_{10}$ CFU counts. Tukey HSD results.

Comparisons	Differences	95% confidence intervals		Adjusted p values	
		Lower	Upper		
CDD:T0-Control:T0	-2.54	-3.85	-1.24	0.00000	****
Control:TGN-Control:T0	0.59	-0.72	1.89	0.95620	NS
CDD:TGN-Control:T0	1.16	-0.15	2.46	0.13330	NS
Control:VAN 20-Control:T0	1.84	0.54	3.15	0.00071	***
CDD:VAN 20-Control:T0	-5.00	-6.30	-3.69	0.00000	****
Control:RIF 2.5-Control:T0	-3.39	-4.69	-2.08	0.00000	****
CDD:RIF 2.5-Control:T0	-6.10	-7.41	-4.80	0.00000	****
Control:LIN 5-Control:T0	-0.62	-1.92	0.69	0.93571	NS
CDD:LIN 5-Control:T0	-3.39	-4.69	-2.08	0.00000	****
Control:MXF 1.5-Control:T0	-2.52	-3.83	-1.22	0.00000	****
CDD:MXF 1.5-Control:T0	-5.09	-6.40	-3.79	0.00000	****
Control:DAP 30-Control:T0	-3.50	-4.80	-2.19	0.00000	****
CDD:DAP 30-Control:T0	-5.45	-6.75	-4.15	0.00000	****
Control:DOX 1.5-Control:T0	-1.06	-2.37	0.24	0.22905	NS
CDD:DOX 1.5-Control:T0	-4.00	-5.30	-2.69	0.00000	****
CDD:TGN-Control:TGN	0.57	-0.74	1.87	0.96787	NS
CDD:VAN 20-Control:VAN 20	-6.84	-8.14	-5.53	0.00000	****
CDD:RIF 2.5-Control:RIF 2.5	-2.72	-4.02	-1.41	0.00000	****
CDD:LIN 5-Control:LIN 5	-2.77	-4.07	-1.46	0.00000	****
CDD:MXF 1.5-Control:MXF 1.5	-2.57	-3.87	-1.26	0.00000	****
CDD:DAP 30-Control:DAP 30	-1.95	-3.26	-0.65	0.00028	***
CDD:DOX 1.5-Control:DOX 1.5	-2.93	-4.24	-1.63	0.00000	****

Table 5. ATCC 35984 (MRSE). Biomass assay (% of T0 control). Tukey HSD results.

Comparisons	Differences	95% confidence intervals		Adjusted p values	
		Lower	Upper		
CDD:T0-Control:T0	-88.5	-118.3	-58.8	0.00000	****
Control:TGN-Control:T0	23.4	-6.3	53.1	0.27459	NS
CDD:TGN-Control:T0	-11.3	-41.0	18.4	0.99056	NS
Control:VAN 20-Control:T0	15.9	-13.8	45.6	0.84551	NS
CDD:VAN 20-Control:T0	-81.6	-111.3	-51.9	0.00000	****
Control:RIF 2.5-Control:T0	4.7	-25.0	34.4	1.00000	NS
CDD:RIF 2.5-Control:T0	-82.7	-112.4	-52.9	0.00000	****
Control:LIN 5-Control:T0	2.3	-27.4	32.0	1.00000	NS
CDD:LIN 5-Control:T0	-77.9	-107.6	-48.2	0.00000	****
Control:MXF 1.5-Control:T0	5.2	-24.5	34.9	1.00000	NS
CDD:MXF 1.5-Control:T0	-78.1	-107.8	-48.4	0.00000	****
Control:DAP 30-Control:T0	21.2	-8.5	50.9	0.42780	NS
CDD:DAP 30-Control:T0	-84.0	-113.7	-54.3	0.00000	****
Control:DOX 1.5-Control:T0	3.3	-26.4	33.0	1.00000	NS
CDD:DOX 1.5-Control:T0	-85.2	-114.9	-55.5	0.00000	****
CDD:TGN-Control:TGN	-34.7	-64.4	-5.0	0.00965	**
CDD:VAN 20-Control:VAN 20	-97.5	-127.2	-67.8	0.00000	****
CDD:RIF 2.5-Control:RIF 2.5	-87.3	-117.0	-57.6	0.00000	****
CDD:LIN 5-Control:LIN 5	-80.3	-110.0	-50.6	0.00000	****
CDD:MXF 1.5-Control:MXF 1.5	-83.2	-112.9	-53.5	0.00000	****
CDD:DAP 30-Control:DAP 30	-105.2	-134.9	-75.5	0.00000	****
CDD:DOX 1.5-Control:DOX 1.5	-88.6	-118.3	-58.9	0.00000	****

Table 6. ATCC 47076 (E. coli). Log$_{10}$ CFU counts. Tukey HSD results.

Comparisons	Differences	95% confidence intervals		Adjusted p values	
		Lower	Upper		
CDD:T0-Control:T0	-1.24	-2.40	-0.08	0.02515	*
Control:TGN-Control:T0	-0.10	-1.26	1.06	1.00000	NS
CDD:TGN-Control:T0	-0.33	-1.49	0.83	0.99942	NS
Control:CEF 3.8-Control:T0	-2.06	-3.31	-0.81	0.00004	****
CDD:CEF 3.8-Control:T0	-7.29	-8.54	-6.04	0.00000	****
Control:CEF 42-Control:T0	-7.05	-8.21	-5.89	0.00000	****
CDD:CEF 42-Control:T0	-7.29	-8.45	-6.14	0.00000	****
Control:CIP 1.625-Control:T0	-3.21	-4.36	-2.05	0.00000	****
CDD:CIP 1.625-Control:T0	-7.19	-8.35	-6.03	0.00000	****
Control:CST 2.5-Control:T0	-1.23	-2.48	0.02	0.05593	NS
CDD:CST 2.5-Control:T0	-6.80	-8.05	-5.55	0.00000	****
Control:MER 0.25-Control:T0	-1.21	-2.46	0.03	0.06433	NS
CDD:MER 0.25-Control:T0	-7.33	-8.58	-6.08	0.00000	****
Control:MER 6.25-Control:T0	-6.81	-7.97	-5.65	0.00000	****
CDD:MER 6.25-Control:T0	-7.27	-8.43	-6.11	0.00000	****
CDD:TGN-Control:TGN	-0.23	-1.39	0.93	0.99999	NS
CDD:CEF 3.8-Control:CEF 3.8	-5.23	-6.56	-3.89	0.00000	****
CDD:CEF 42-Control:CEF 42	-0.24	-1.40	0.92	0.99999	NS
CDD:CIP 1.625-Control:CIP 1.625	-3.98	-5.14	-2.83	0.00000	****
CDD:CST 2.5-Control:CST 2.5	-5.57	-6.90	-4.23	0.00000	****
CDD:MER 0.25-Control:MER 0.25	-6.11	-7.45	-4.78	0.00000	****
CDD:MER 6.25-Control:MER 6.25	-0.46	-1.62	0.70	0.98238	NS

Table 7. ATCC 47076 (E. coli). Biomass assay (% of T0 control). Tukey HSD results.

Comparisons	Differences	95% confidence intervals		Adjusted p values	
		Lower	Upper		
CDD:T0-Control:T0	-80.3	-126.2	-34.3	0.00001	****
Control:TGN-Control:T0	16.1	-29.8	62.0	0.99498	NS
CDD:TGN-Control:T0	13.5	-32.4	59.4	0.99924	NS
Control:CEF 3.8-Control:T0	-61.7	-111.3	-12.1	0.00415	**
CDD:CEF 3.8-Control:T0	-99.1	-148.7	-49.5	0.00000	****
Control:CEF 42-Control:T0	-86.0	-131.9	-40.1	0.00000	****
CDD:CEF 42-Control:T0	-92.5	-138.5	-46.6	0.00000	****
Control:CIP 1.625-Control:T0	-48.3	-94.3	-2.4	0.03043	*
CDD:CIP 1.625-Control:T0	-97.3	-143.2	-51.4	0.00000	****
Control:CST 2.5-Control:T0	-24.6	-70.5	21.4	0.84212	NS
CDD:CST 2.5-Control:T0	-84.9	-130.8	-38.9	0.00000	****
Control:MER 0.25-Control:T0	4.8	-44.8	54.4	1.00000	NS
CDD:MER 0.25-Control:T0	-93.4	-143.0	-43.8	0.00000	****
Control:MER 6.25-Control:T0	-82.9	-128.9	-37.0	0.00001	****
CDD:MER 6.25-Control:T0	-93.8	-139.7	-47.8	0.00000	****
CDD:TGN-Control:TGN	-2.6	-48.5	43.3	1.00000	NS
CDD:CEF 3.8-Control:CEF 3.8	-37.4	-90.4	15.7	0.45113	NS
CDD:CEF 42-Control:CEF 42	-6.6	-52.5	39.4	1.00000	NS
CDD:CIP 1.625-Control:CIP 1.625	-49.0	-94.9	-3.0	0.02665	*
CDD:CST 2.5-Control:CST 2.5	-60.3	-106.2	-14.4	0.00194	**
CDD:MER 0.25-Control:MER 0.25	-98.2	-151.2	-45.2	0.00000	****
CDD:MER 6.25-Control:MER 6.25	-10.8	-56.7	35.1	0.99995	NS

3   Two-way ANOVAs results

Table 8

ATCC 33591 (MRSA). Two-way ANOVA results using the $\log_{10}$ CFU counts as the criterion

Predictor	Sum of Squares	df	Mean Square	F	p	partial η^2	partial η^2 90% CI [LL, UL]
(Intercept)	1449.57	1	1449.57	8707.75	.000		
CDD exposure	59.28	1	59.28	356.11	.000	.92	[.86, .94]
Antibiotics exposure	147.16	6	24.53	147.34	.000	.97	[.93, .97]
CDD exposure x Antibiotics exposure	21.22	6	3.54	21.25	.000	.80	[.63, .83]
Error	5.33	32	0.17				

Note. LL and UL represent the lower-limit and upper-limit of the partial η^2 confidence interval, respectively.

Table 9

ATCC 33591 (MRSA). Two-way ANOVA results using the biomass (% of T0 control) as the criterion

Predictor	Sum of Squares	df	Mean Square	F	p	partial η^2	partial η^2 90% CI [LL, UL]
(Intercept)	212225.00	1	212225.00	5587.20	.000		
CDD exposure	90525.70	1	90525.70	2383.25	.000	.99	[.98, .99]
Antibiotics exposure	24406.45	6	4067.74	107.09	.000	.95	[.91, .96]
CDD exposure x Antibiotics exposure	13014.65	6	2169.11	57.11	.000	.91	[.83, .92]
Error	1291.46	34	37.98				

Note. LL and UL represent the lower-limit and upper-limit of the partial η^2 confidence interval, respectively.

Table 10

ATCC 35984 (MRSE). Two-way ANOVA results using the log$_{10}$ CFU counts as the criterion

Predictor	Sum of Squares	*df*	Mean Square	*F*	*p*	partial η^2	partial η^2 90% CI [LL, UL]
(Intercept)	661.86	1	661.86	3992.47	.000		
CDD exposure	88.73	1	88.73	535.24	.000	.94	[.91, .96]
Antibiotics exposure	147.56	7	21.08	127.16	.000	.97	[.93, .97]
CDD exposure x Antibiotics exposure	42.68	7	6.10	36.78	.000	.89	[.78, .90]
Error	5.30	32	0.17				

Note. LL and UL represent the lower-limit and upper-limit of the partial η^2 confidence interval, respectively.

Table 11

ATCC 35984 (MRSE). Two-way ANOVA results using the biomass (% of T0 control) as the criterion

Predictor	Sum of Squares	*df*	Mean Square	*F*	*p*	partial η^2	partial η^2 90% CI [LL, UL]
(Intercept)	221395.68	1	221395.68	2275.06	.000		
CDD exposure	83023.52	1	83023.52	853.15	.000	.96	[.94, .97]
Antibiotics exposure	10680.41	7	1525.77	15.68	.000	.77	[.57, .81]
CDD exposure x Antibiotics exposure	4683.78	7	669.11	6.88	.000	.60	[.30, .65]
Error	3114.06	32	97.31				

Note. LL and UL represent the lower-limit and upper-limit of the partial η^2 confidence interval, respectively.

Table 12

ATCC 47076 (E. coli). Two-way ANOVA results using the $\log_{10}$ CFU counts as the criterion

Predictor	Sum of Squares	df	Mean Square	F	p	partial η^2	partial η^2 90% CI [LL, UL]
(Intercept)	801.94	1	801.94	3518.29	.000		
CDD exposure	142.93	1	142.93	627.07	.000	.95	[.92, .97]
Antibiotics exposure	178.80	5	35.76	156.89	.000	.96	[.93, .97]
CDD exposure x Antibiotics exposure	53.17	5	10.63	46.65	.000	.89	[.78, .91]
Error	6.84	30	0.23				

Note. LL and UL represent the lower-limit and upper-limit of the partial η^2 confidence interval, respectively.

Table 13

ATCC 47076 (E. coli). Two-way ANOVA results using the biomass (% of T0 control) as the criterion

Predictor	Sum of Squares	df	Mean Square	F	p	partial η^2	partial η^2 90% CI [LL, UL]
(Intercept)	127753.01	1	127753.01	355.84	.000		
CDD exposure	33719.94	1	33719.94	93.92	.000	.75	[.59, .81]
Antibiotics exposure	47008.62	5	9401.72	26.19	.000	.80	[.64, .84]
CDD exposure x Antibiotics exposure	8678.67	5	1735.73	4.83	.002	.43	[.12, .52]
Error	11488.71	32	359.02				

Note. LL and UL represent the lower-limit and upper-limit of the partial η^2 confidence interval, respectively.